Global Sitagliptin Market 2023-2030

    In Stock

    Coming Soon 

    GLOBAL SITAGLIPTIN MARKET

     

    INTRODUCTION

    Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type two diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet XR).

     

    Common side effects include headaches, swelling of the legs, and upper respiratory tract infections. Serious side effects may include angioedema, low blood sugar, kidney problems, pancreatitis, and joint pain. Whether use in pregnancy or breastfeeding is safe is unclear. It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.

     

    Adverse effects from sitagliptin are similar to placebo, except for rare nausea, common cold-like symptoms, and photosensitivity. It does not increase the risk of diarrhea. No significant difference exists in the occurrence of hypoglycemia between placebo and sitagliptin. In those taking sulphonylureas, the risk of low blood sugar is increased. 

    GLOBAL SITAGLIPTIN MARKET SIZE AND FORECAST

     

    infographic: Sitagliptin Market , Sitagliptin Market Size, Sitagliptin Market Trends, Sitagliptin Market Forecast, Sitagliptin Market Risks, Sitagliptin Market Report, Sitagliptin Market Share.

     

    The Global Sitagliptin Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

     

    NEW PRODUCT LAUNCH

    Netmeds SitagliptinSITAGLIPTIN belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors used in treating type 2 diabetes in adults. SITAGLIPTIN is prescribed for the condition of type 2 diabetes when diet and exercise alone cannot control their blood sugar levels. It is the first-line therapy for patients with type 2 diabetes that restores the body’s response to insulin.

     

    Insulin is the hormone that controls sugar levels in your blood. People with type 2 diabetes either do not produce enough insulin, or the insulin produced cannot perform its function in the body (insulin resistance).

     

    Middle-aged or older individuals are most likely to suffer from type 2 diabetes, so it is also known as adult-onset diabetes.

     

    SITAGLIPTIN contains sitagliptin. SITAGLIPTIN work by blocking the action of DPP-4 (an enzyme which destroys the hormone ‘Incretin’). The enzyme ‘Incretins’ helps produce more insulin only when required and reduces blood sugar produced by the liver when not needed.

     

    SITAGLIPTIN should be taken with food or an empty stomach. However, it should be taken at the same time of the day each time for the best results. For better advice, your doctor will decide what dose should be taken, which can change quickly depending on your condition.

     

    The most common side effect of SITAGLIPTIN is hypoglycaemia (low blood glucose levels), upper respiratory tract infection, nasopharyngitis (infection of the nose and throat with common cold) and headache.

    COMPANY PROFILE

     

    THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

    1. How many Sitagliptin are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Global Sitagliptin and key vendor selection criteria
    3. Where is the Sitagliptin manufactured? What is the average margin per unit?
    4. Market share of Global Sitagliptin market manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Global Sitagliptin in-house
    6. key predictions for next 5 years in Global Sitagliptin market
    7. Average B-2-B Sitagliptin market price in all segments
    8. Latest trends in Sitagliptin market, by every market segment
    9. The market size (both volume and value) of the Sitagliptin market in 2023-2030 and every year in between?
    10. Production breakup of Sitagliptin market, by suppliers and their OEM relationship

     

    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2023-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2023-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2023-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2023-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
     
    0
      0
      Your Cart
      Your cart is emptyReturn to Shop